Suchen
Nasus Pharma Ltd
NSRXZur Watchlist hinzufügen
2.890USD
-0.085-2.86%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
33.84MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Nasus Pharma Ltd Unternehmen
Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.
Nasus Pharma Ltd Informationen
BörsenkürzelNSRX
Name des UnternehmensNasus Pharma Ltd
IPO-datumAug 13, 2025
CEOTeleman (Dan)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeAug 13
AddresseYigal Alon 65
StadtTEL AVIV-YAFO
BörseNASDAQ OMX – NASDAQ Basic Amex
LandIsrael
Postleitzahl- -
Telefon97237326616
Websitehttps://www.nasuspharma.com
BörsenkürzelNSRX
IPO-datumAug 13, 2025
CEOTeleman (Dan)
Führungskräfte von Nasus Pharma Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.92M
+1.20%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
--
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Mr. Ronnie Hershman
Mr. Ronnie Hershman
Independent Director
Independent Director
--
--
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Isaac Israel
Isaac Israel
Independent Director Nominee
Independent Director Nominee
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.92M
+1.20%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
--
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Gilboa (Udi)
16.43%
Megiddo (Dalia)
16.13%
Hershman Holdings L.L.C.
7.76%
Balyasny Asset Management LP
7.67%
Cable Car Capital LLC
5.23%
Andere
46.77%
Aktionäre
Aktionäre
Anteil
Gilboa (Udi)
16.43%
Megiddo (Dalia)
16.13%
Hershman Holdings L.L.C.
7.76%
Balyasny Asset Management LP
7.67%
Cable Car Capital LLC
5.23%
Andere
46.77%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
32.77%
Corporation
16.34%
Hedge Fund
7.67%
Investment Advisor/Hedge Fund
5.62%
Investment Advisor
0.04%
Andere
37.55%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q4
2
3.24K
0.00%
--
2026Q1
5
1.56M
13.34%
+1.56M
2025Q4
2
2.38K
0.03%
+1.14K
2025Q3
7
5.35M
59.33%
+5.35M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Gilboa (Udi)
1.90M
16.24%
+55.29K
+3.00%
Sep 30, 2025
Megiddo (Dalia)
1.89M
16.13%
+42.85K
+2.32%
Sep 30, 2025
Hershman Holdings L.L.C.
891.19K
7.61%
+414.18K
+86.83%
Sep 30, 2025
Capital Point Ltd
575.13K
4.91%
+575.13K
--
Aug 14, 2025
Phoenix Solutions Ltd
429.31K
3.67%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
378.00
0%
-863.00
-69.54%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
